Clinical Trial Update: Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST [Phase 2]

View source ↗

Summary

A Phase 2 study assessing regorafenib as a single agent in first-line treatment of metastatic/unresectable KIT/PDGFR wild-type gastrointestinal stromal tumors (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Grupo Espanol de Investigacion en Sarcomas | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: COMPLETED